Business
-
Belgian biotech Cannovex and Dutch DPI developer PureIMS announced that Cannovex has acquired exclusive rights to develop pharmaceutical cannabinoid products delivered via PureIMS’s Cyclops high-dose dry powder inhaler. The companies say that they have entered… Read more . . .
-
According to Agomab, the US Patent and Trademark Office (USPTO) has granted a composition of matter patent (US Patent No. 12,577,230) covering the company’s AGMB-447 inhaled ALK5 (TGFβR1) inhibitor through 2041. Agomab is developing AGMB-447… Read more . . .
-
Everest Medicines announced that it has acquired Chinese development, manufacturing, and commercialization rights to Cardamyst etripamil nasal spray from Corxel Pharmaceuticals Hong Kong (formerly Ji Xing Pharmaceuticals). Ji Xing acquired the Chinese rights to etripamil… Read more . . .
-
US biopharm Esperion will pay $75 million in cash up front and up to $180 million in milestone payments to acquire Corstasis Therapeutics and its Enbumyst bumetanide nasal spray, the companies said. The deal also… Read more . . .
-
According to Pulmatrix, Cullgen has terminated the 2024 merger agreement between the companies. Pulmatrix said that it would In December 2025, Pulmatrix and Cullgen announced that Chinese authorities had still not approved the merger, and… Read more . . .
-
A consortium called NOFLU has received €13 million from the European Health and Digital Executive Agency (HaDEA) under the EU4Health program to support development of an intranasal vaccine against influenza. The NOFLU consortium consists of… Read more . . .
-
Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried… Read more . . .
-
UK-based Essential Pharma announced that it has acquired the rights to market Bayer’s Ventavis iloprost trometamol inhalation solution for the treatment of primary pulmonary hypertension in all markets except for the US and Russia. Essential… Read more . . .
-
Iliad Biotechnologies announced that it has raised $115 million in a Series B financing to support continued development of the company’s BPZE1 intranasal vaccine against pertussis (whooping cough). The company said that it intends to… Read more . . .
-
Israeli psychedelic drug developer Clearmind Medicine has signed an agreement with Polyrizon for development of an intranasal formulation of Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) based on Polyrizon’s intranasal hydrogel technology, the companies said. According to Clearmind, MEAI… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK